Kalehua Capital Management
Kalehua Capital Management reported 22 stocks worth $132M in its 13F filing for Q3 2026, filed Nov 13, 2026. Its largest holdings are MANE (13.3%), BOXX (13.3%) and KRSA (10.7%). Compared with Q2 2026, the fund opened new positions in KRSA, BETRF and OBX, added to KRRO, trimmed MANE, BOXX and XFOR and sold out of CMPS, SION and PHVS.
Latest filing: what Kalehua Capital Management did in Q3 2026
vs Q2 2026
KRRO+$679K+17%
Dollar changes use the share change at the quarter end price. New and sold out show the whole position.
Portfolio at a glance
share of reported value · Q3 2026Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 4 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 | ![]() MANE Veradermics Inc | $17.7M | 13.3% | 146K | −146K (−50%) | 3 of 4 | |
| 2 | ![]() BOXX EA Series Trust | $17.6M | 13.3% | 148K | −78K (−34%) | 4 of 4 | |
| 3 | ![]() KRSA Korsana Biosciences Inc | $14.2M | 10.7% | 443K | New position | 1 of 4 | |
| 4 | ![]() XFOR X4 Pharmaceuticals Inc | $10.8M | 8.2% | 3.7M | −3.7M (−50%) | 4 of 4 | |
| 5 | ![]() ACRS Aclaris Therapeutics Inc | $9.6M | 7.3% | 1.8M | −1.8M (−50%) | 3 of 4 | |
| 6 | ![]() SRZN Surrozen Inc | $9.2M | 7.0% | 286K | −484K (−63%) | 4 of 4 | |
| 7 | ![]() IKT Inhibikase Therapeutics Inc | $7.9M | 5.9% | 3.8M | −3.8M (−50%) | 4 of 4 | |
| 8 | ![]() SEPN Septerna Inc | $7.6M | 5.8% | 195K | −195K (−50%) | 4 of 4 | |
| 9 | ![]() BETRF Betterlife Pharma Inc | $6.7M | 5.0% | 27.7M | New position | 1 of 4 | |
| 10 | ![]() OBX Obsidian Therapeutics Inc | $5.7M | 4.3% | 417K | New position | 1 of 4 |
Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q2 2026, gone in Q3 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
![]() CMPS Compass Pathways PLC | $23.2M | 1.6M |
![]() SION Sionna Therapeutics Inc | $17.3M | 394K |
![]() PHVS Pharvaris N V | $13.7M | 398K |
![]() KPTI Karyopharm Therapeutics Inc | $13.4M | 1.4M |
CYCLERION THERAPEUTICS INC | $11.2M | 3.3M |
🔒 Free account: see all 12.
Reported value
last 4 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q3 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Nov 13, 2026 | 13F-HR | Q3 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Kalehua Capital Management 13F FAQ
What does Kalehua Capital Management own?
Kalehua Capital Management reported 22 stocks worth $132M in its 13F filing for Q3 2026, filed Nov 13, 2026. Its largest holdings are MANE (13.3%), BOXX (13.3%) and KRSA (10.7%). The table above lists every position in the filing (the top 10 without an account).
What did Kalehua Capital Management buy and sell in Q3 2026?
Compared with Q2 2026: 8 new positions, 1 added to, 13 trimmed and 12 sold out. New positions include KRSA, BETRF and OBX. It sold all of CMPS, SION and PHVS.
When will Kalehua Capital Management file its next 13F?
Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.
How much is Kalehua Capital Management's portfolio worth?
The Q3 2026 filing reports $132M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.

BETRF












